These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28130133)

  • 1. Inhalable bioresponsive chitosan microspheres of doxorubicin and soluble curcumin augmented drug delivery in lung cancer cells.
    Jyoti K; Pandey RS; Kush P; Kaushik D; Jain UK; Madan J
    Int J Biol Macromol; 2017 May; 98():50-58. PubMed ID: 28130133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble curcumin amalgamated chitosan microspheres augmented drug delivery and cytotoxicity in colon cancer cells: In vitro and in vivo study.
    Jyoti K; Bhatia RK; Martis EAF; Coutinho EC; Jain UK; Chandra R; Madan J
    Colloids Surf B Biointerfaces; 2016 Dec; 148():674-683. PubMed ID: 27701049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
    Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
    Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer.
    Gu Y; Li J; Li Y; Song L; Li D; Peng L; Wan Y; Hua S
    Int J Nanomedicine; 2016; 11():5757-5770. PubMed ID: 27843316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of a novel phytosome-loaded chitosan microsphere system for curcumin delivery.
    Zhang J; Tang Q; Xu X; Li N
    Int J Pharm; 2013 May; 448(1):168-74. PubMed ID: 23524117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalable, bioresponsive microparticles for targeted drug delivery in the lungs.
    Sivadas N; Cryan SA
    J Pharm Pharmacol; 2011 Mar; 63(3):369-75. PubMed ID: 21749384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-sensitive polymeric nanoparticles of mPEG-PLGA-PGlu with hybrid core for simultaneous encapsulation of curcumin and doxorubicin to kill the heterogeneous tumour cells in breast cancer.
    Yuan JD; ZhuGe DL; Tong MQ; Lin MT; Xu XF; Tang X; Zhao YZ; Xu HL
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):302-313. PubMed ID: 29301415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
    Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
    Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach.
    Tefas LR; Sylvester B; Tomuta I; Sesarman A; Licarete E; Banciu M; Porfire A
    Drug Des Devel Ther; 2017; 11():1605-1621. PubMed ID: 28579758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Chitosan-Based pH-Sensitive Polymeric Micelles Containing Curcumin for Colon-Targeted Drug Delivery.
    Woraphatphadung T; Sajomsang W; Rojanarata T; Ngawhirunpat T; Tonglairoum P; Opanasopit P
    AAPS PharmSciTech; 2018 Apr; 19(3):991-1000. PubMed ID: 29110292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
    Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
    Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
    Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
    Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hierarchical bioresponsive nanocarriers for codelivery of curcumin and doxorubicin.
    Lin JT; Ye QB; Yang QJ; Wang GH
    Colloids Surf B Biointerfaces; 2019 Aug; 180():93-101. PubMed ID: 31035057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line.
    Shali H; Shabani M; Pourgholi F; Hajivalili M; Aghebati-Maleki L; Jadidi-Niaragh F; Baradaran B; Movassaghpour Akbari AA; Younesi V; Yousefi M
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):293-302. PubMed ID: 28362176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimuli-sensitive hollow spheres from chitosan-graft-β-cyclodextrin for controlled drug release.
    Yu N; Li G; Gao Y; Liu X; Ma S
    Int J Biol Macromol; 2016 Dec; 93(Pt A):971-977. PubMed ID: 27663551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer.
    Lee R; Choi YJ; Jeong MS; Park YI; Motoyama K; Kim MW; Kwon SH; Choi JH
    Bioconjug Chem; 2020 Mar; 31(3):923-932. PubMed ID: 32027493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a novel biocompatible magnetic nanomedicine based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast cancer.
    Rastegar R; Akbari Javar H; Khoobi M; Dehghan Kelishadi P; Hossein Yousefi G; Doosti M; Hossien Ghahremani M; Shariftabrizi A; Imanparast F; Gholibeglu E; Gholami M
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):207-216. PubMed ID: 29688063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies.
    Jyoti K; Kaur K; Pandey RS; Jain UK; Chandra R; Madan J
    J Colloid Interface Sci; 2015 May; 445():219-230. PubMed ID: 25622047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.